Source: FirstWord Pharma

XBiotech: XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

AUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-...

Read full article »
Annual Revenue
$4M
Employees
100
John Simard's photo - Chairman & CEO of XBiotech

Chairman & CEO

John Simard

CEO Approval Rating

80/100

Read more